Cardiogenic Shock Clinical Trial
— SHOCK-COOLOfficial title:
Randomized Pilot Study of Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction
NCT number | NCT01890317 |
Other study ID # | HZLCOOL1 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | August 2012 |
Est. completion date | March 2016 |
Verified date | July 2018 |
Source | University of Leipzig |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Prospective, randomized, single-center, controlled, open-label Pilot-study to investigate whether induction of mild hypothermia in addition to primary percutaneous coronary intervention and optimal medical therapy in myocardial infarction complicated by cardiogenic shock improves cardiac power index after 24 h.
Status | Completed |
Enrollment | 40 |
Est. completion date | March 2016 |
Est. primary completion date | November 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Acute myocardial infarction complicated by cardiongenic shock - Patients on mechanical ventilation at time of randomization Exclusion Criteria: - Out of hospital resuscitation with indication for mild hypothermia - mechanical complications after acute myocardial infarction - duration of cardiogenic shock > 12 hours - age > 90 years |
Country | Name | City | State |
---|---|---|---|
Germany | Department of Internal Medicine/Cardiology, University of Leipzig - Heart Center | Leipzig | Sachsen |
Lead Sponsor | Collaborator |
---|---|
University of Leipzig |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cardiac Power Index after 24 hr. | Cardiac Power Index after 24 hours as surrogate endpoint. | 24 hours | |
Secondary | 30-days mortality | 30 days | ||
Secondary | Change of hemodynamics over the first 48 hr. | During first 48 hr | ||
Secondary | Catecholamine dose and duration of catecholamine support | 30 days | ||
Secondary | Length of ICU-stay | 30 days | ||
Secondary | Length of mechanical ventilation | 30 days | ||
Secondary | SAPS-II-Score | Simplified Acute Physiology Score for the first 4 days | 96 hours | |
Secondary | Severe and moderate bleeding complications (GUSTO-definition) | 30 days | ||
Secondary | Sepsis | 30 days | ||
Secondary | Pneumonia | 30 days | ||
Secondary | Stroke | 30 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03283995 -
Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology
|
||
Active, not recruiting |
NCT04325035 -
The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock
|
Phase 2 | |
Active, not recruiting |
NCT05100836 -
SURPASS Impella 5.5 Study
|
||
Not yet recruiting |
NCT05106491 -
Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients
|
N/A | |
Completed |
NCT02301819 -
ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock
|
N/A | |
Completed |
NCT01367743 -
Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock
|
Phase 4 | |
Recruiting |
NCT05728359 -
Genomic Determinants of Outcome in Cardiogenic Shock
|
||
Recruiting |
NCT05699005 -
Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO
|
Phase 1 | |
Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
Completed |
NCT03436641 -
Microcirculation in Cardiogenic Shock
|
||
Recruiting |
NCT03313687 -
SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK
|
||
Recruiting |
NCT05506449 -
The RECOVER IV Trial
|
N/A | |
Completed |
NCT04144660 -
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
|
||
Completed |
NCT04548739 -
Cerebral Autoregulation in Pediatric ECMO (ECMOX 2)
|
||
Recruiting |
NCT04141410 -
Global Longitudinal Strain Assessment in Cardiogenic Shock During Sepsis
|
||
Not yet recruiting |
NCT05879276 -
Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.
|
Phase 3 | |
Enrolling by invitation |
NCT05570864 -
Score TO Predict SHOCK - STOP SHOCK
|
||
Completed |
NCT02591771 -
Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock
|
Phase 2 | |
Terminated |
NCT02279979 -
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
|
N/A | |
Completed |
NCT01374867 -
CardShock Study and Registry
|
N/A |